In recent years, many patients like Mitchell have faced soaring insulin costs. These prices have been exacerbated by pharmacy benefit managers, or PBMs, middlemen between drug manufacturers and ...

The lawsuits generally make two claims: that insulin prices are unreasonably high and that drug companies and PBMs are responsible. The lawsuits are on firmer ground in their claim that PBMs are ...

INSULIN LITIGATION DEEP-DIVE — As Congress weighs legislation to rein in pharmacy benefit managers, a lawsuit accusing PBMs and insulin makers of racketeering and unfair trade practices is ...

Anyone who needs insulin to treat diabetes knows that the cost of the drug has skyrocketed in the last few years. The reason for the sharp ...

The companies, known as PBMs, are accused of excluding available insulin products with lower prices — which could have been more affordable for patients — in favor of higher-priced insulins ...

Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

Five things to know: 1. Insulin manufacturers named in the suit are Eli Lilly, Novo Nordisk and Sanofi. PBMs named in the suit include CVS' Caremark, UnitedHealth's Optum Rx and Cigna's Express ...

Even when lower list-price insulins became available, the PBMs excluded those options for patients and provided higher prices and highly rebated insulin products, the agency alleges. "Millions of ...

The suit follows legal action over insulin pricing taken by other states, including Arkansas, Kansas, Mississippi, and Minnesota. "We're fighting back against drug companies and PBMs that ...

The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and ...

alleging their practices drive insulin manufacturers to raise prices and enable PBMs to capture higher rebates and fees at the expense of some patients. Also last month, Sen. Bernie Sanders (I-VT.) ...

Even when lower list-price insulins became available, the PBMs excluded those options for patients and provided higher prices and highly rebated insulin products, the agency alleges. "Millions of ...